Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001123292-24-000396
Filing Date
2024-12-19
Accepted
2024-12-19 16:15:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4827
  Complete submission text file 0001123292-24-000396.txt   6628
Mailing Address 333 LAKESIDE DR FOSTER CITY CA 94404
Business Address 333 LAKESIDE DR FOSTER CITY CA 94404 6505743000
GILEAD SCIENCES, INC. (Filed by) CIK: 0000882095 (see all company filings)

EIN.: 943047598 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Subject) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92962 | Film No.: 241563452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)